Representational image
New Delhi: Shasun Pharmaceuticals on Monday pronounced it has perceived capitulation of a US Food and Drug Administration (FDA) curtsy to marketplace pain use drug Carisoprodol in a US.
Shasun Pharmaceuticals in a BSE filing said, “It has perceived capitulation from a United States Food and Drug Administration (US FDA) for Carisoprodol tablets.”
The capitulation is for a 250 mg and 350 mg strengths. Shasun Pharma pronounced Carisoprodol tablets of 250 mg and 350 mg have sales of approximately $38 million.
“While a 350 mg has a few general players, Shasun expects to be a initial marketed general actor in a $16 million Carisoprodol tablets of 250 mg opportunity,” it added.
Shasun Pharmaceuticals pronounced a product will be made during a Puducherry plant and distributed by a partner. It is approaching to be launched shortly.
At 2:07 p.m., shares in Shasun Pharmaceuticals were trade 2.25 per cent aloft during Rs 406.90 every on a BSE, whose benchmark Sensex index was adult 0.79 per cent.
This entrance upheld by a Full-Text RSS use – if this is your calm and you’re reading it on someone else’s site, greatfully review a FAQ during fivefilters.org/content-only/faq.php#publishers.
